

HBEC Line	Enriched miRNAs	<i>p</i> -value	Reduced miRNAs	<i>p</i> -value
<b>KRAS</b>	hsa-miR-4448-3p	2.91E-09	hsa-miR-769-5p	2.68E-04
	hsa-miR-423-3p	7.13E-05	hsa-miR-4791-5p	3.89E-04
	hsa-miR-4488-5p	7.23E-05	hsa-miR-339-5p	6.80E-04
	hsa-miR-423-5p	2.88E-04		
	hsa-miR-328-3p	3.79E-04		
	hsa-miR-3182-5p	6.33E-04		
	hsa-miR-224-5p	9.42E-04		
	hsa-miR-320a-3p	1.08E-03		
<b>p53/KRAS</b>	hsa-miR-4448-3p	4.65E-13	hsa-let-7c-5p	5.52E-06
	hsa-miR-6131-3p	1.75E-08	hsa-miR-100-5p	2.29E-05
	hsa-miR-3182-5p	3.21E-08	hsa-miR-4497-5p	4.82E-05
	hsa-miR-1273a-5p	9.14E-05	hsa-miR-29b-1-3p	2.64E-04
	hsa-miR-5585-3p	4.73E-04	hsa-miR-125b-2-5p	3.00E-04
	hsa-miR-34b-3p	7.70E-04	hsa-miR-654-3p	1.09E-03
	hsa-miR-1273d-3p	9.59E-04	hsa-miR-221-3p	1.12E-03
			hsa-miR-4791-5p	1.40E-03
			hsa-miR-181b-1-5p	1.43E-03
<b>p53/EGFR</b>	hsa-miR-4448-3p	4.49E-12	hsa-miR-3168-5p	1.31E-05
	hsa-miR-3182-5p	3.10E-07	hsa-miR-7641-1-3p	4.92E-05
	hsa-miR-6131-3p	3.92E-06	hsa-miR-4497-5p	1.15E-04
<b>p53/KRAS/LKB1</b>	hsa-miR-4448-3p	2.34E-07	hsa-miR-92b-5p	1.52E-05
	hsa-miR-34b-3p	1.55E-04	hsa-miR-100-5p	9.19E-05
	hsa-miR-3182-5p	4.35E-04	hsa-miR-1289-1-3p	2.38E-04
	hsa-miR-200b-5p	5.63E-04	hsa-miR-125b-2-5p	3.79E-04
	hsa-miR-200c-3p	8.34E-04		

		Invasive Breast Carcinoma		Benign Fibroadenoma
		ER <sup>+</sup>	ER <sup>-</sup>	
Patient Age at Collection (years)				
	< 40	2	3	14
	40-60	8	8	5
	60-80	4	9	1
	> 80	2	-	-
	Median	54.9	59.2	33.7
Tumour Subtype				
	ER <sup>+</sup>	16	-	NA
	PR <sup>+</sup>	12	2	NA
	HER2 <sup>+</sup>	6	1	NA
	TNBC	-	17	NA
Tumour Size (mm)				
	Range	12-90	3-80*	NA
	Median	25	18	NA
Tumour Grade (n)				
	1	-	1	NA
	2	-	1	NA
	3	16	18	NA
In Situ Disease (DCIS) (n)				
		11	13	NA
Lymphovascular Invasion (n)				
		3	3	NA
Multifocality (n)				
		3	3	NA
Multicentricity (n)				
		2	1	NA
Lymph Node (n)				
	Positive	9	8	NA
	Negative	7	12	NA

\* Incomplete information available

Benign Fibroadenoma	FDR-value	Invasive Breast Carcinoma	FDR-value
hsa-miR-7-2-5p	7.34E-05	hsa-miR-7641-1-3p	5.92E-06
hsa-miR-7-1-5p	7.38E-05	hsa-miR-375-3p	5.83E-05
hsa-miR-7-3-5p	7.39E-05	hsa-miR-7641-2-3p	1.06E-03
hsa-miR-1-1-3p	1.31E-04	hsa-miR-6131-3p	2.24E-03
hsa-miR-1-2-3p	1.31E-04	hsa-miR-423-5p	4.57E-03
hsa-miR-184-3p	4.12E-04	hsa-miR-3182-5p	7.22E-03
hsa-miR-224-5p	3.93E-03	hsa-miR-146a-5p	9.32E-03
hsa-miR-1246-5p	4.15E-03	hsa-miR-409-3p	1.36E-02
hsa-miR-27a-3p	1.58E-02	hsa-miR-4433b-3p	1.39E-02
hsa-miR-130b-3p	2.32E-02	hsa-miR-320a-3p	1.41E-02
hsa-miR-105-1-5p	2.78E-02	hsa-miR-4488-5p	1.61E-02
hsa-miR-105-2-5p	2.78E-02	hsa-miR-4492-3p	1.72E-02
hsa-miR-582-3p	3.10E-02	hsa-miR-625-3p	1.77E-02
hsa-miR-204-5p	3.31E-02	hsa-miR-1273h-3p	2.10E-02
hsa-miR-454-3p	3.61E-02	hsa-miR-328-3p	2.43E-02
hsa-miR-31-5p	4.36E-02	hsa-miR-654-3p	2.96E-02
hsa-miR-365a-3p	4.50E-02	hsa-miR-3960-3p	3.93E-02
hsa-miR-365b-3p	4.73E-02	hsa-miR-3615-3p	3.98E-02
		hsa-miR-148a-3p	4.47E-02
		hsa-miR-148a-5p	4.53E-02
		hsa-miR-3168-5p	4.59E-02
		hsa-miR-505-5p	4.72E-02
		hsa-miR-136-3p	4.85E-02

		NSCLC	Benign
Patient Age at Collection (years)	40-60	2	4
	60-80	9	10
	>80	1	-
Gender	Male	6	7
	Female	6	7
Tumour Stage (TNM)	IA1	1	NA
	IA2	3	NA
	IA3	1	NA
	IB	6	NA
	IIIA	1	NA
Lymph Node Status	N0	11	NA
	N1	-	NA
	N2	1	NA